Mehdi Rajabi

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Genome Wide Identification

Diabetic Retinopathy

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Kavitha Godugu, Mehdi Rajabi, Shaker A Mousa
RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin α v β 3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13 , 2780. Cancers 16 (10) (2024)
Kavitha Godugu, Mehdi Rajabi, Shaker A Mousa
RETRACTED: Godugu et al. Anti-Cancer Activities of Thyrointegrin α v β 3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13 , 2780. Cancers 16 (10) (2024)
Gennadi V Glinsky, Kavitha Godugu, Thangirala Sudha, Mehdi Rajabi, Sridar V Chittur, Aleck A Hercbergs, Shaker A Mousa, Paul J Davis
Effects of Anticancer Agent P-bi-TAT on Gene Expression Link the Integrin Thyroid Hormone Receptor to Expression of Stemness and Energy Metabolism Genes in Cancer Cells. Metabolites 12 (4) (2022)
Kavitha Godugu, Mehdi Rajabi, Shaker A Mousa
Correction: Godugu et al. Anti-Cancer Activities of Thyrointegrin α v β 3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 2021, 13 , 2780. Cancers 14 (21) (2022)
Kavitha Godugu, Mehdi Rajabi, Shaker A Mousa
Anti-Cancer Activities of Thyrointegrin αvβ3 Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in Glioblastoma. Cancers 13 (11) (2021)